RxDoctor Payments Data

James Arceo, PA

Surgical · Owosso, MINPI 1821032566

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,478 of the $2,316 with a category attached, or 63.8%. Boston Scientific accounts for 76.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $1,446 and has fallen 81.6% since, to $266 in 2025. Among surgical clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,316in general payments, 2019–2025

Across 67 payments — averaging $34.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Abbott$128
  • Averitas Pharma Inc.$98
  • Bioventus LLC$86
  • Medtronic$64
  • Globus Medical$34
  • plus $128 from 5 others

What the payments were for

  • Travel & lodging$81735%
  • Food & beverage$1,47864%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,316 in reported general payments places this provider in the 90th percentile of 229 surgical providers in Michigan.

See all surgical providers in Michigan

Medicare billing

Part B allowed, 2024
$27,494
Medicare patients
167
Services billed
455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,539$19,583
MovantikNaloxegol Oxalate23$15,818
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen659$9,366
Gabapentin435$6,875
Lidocaine85$6,258
Hysingla ErHydrocodone Bitartrate11$5,541
Pregabalin233$4,782
Morphine Sulfate ErMorphine Sulfate100$3,780
Diclofenac Sodium105$2,922
Oxycodone Hcl69$1,624
Naloxone Hcl22$1,466
Tramadol Hcl325$1,452
Duloxetine Hcl69$1,198
Tizanidine Hcl92$1,114
Morphine Sulfate48$1,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAMorphine Sulfate$21$1,01148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 229 surgical providers in Michigan.

Other surgical in Owosso

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →